Evolus, Inc. Common Stock
EOLSEvolus, Inc. (EOLS) is a medical aesthetics company specializing in products for facial aesthetic procedures. The company is best known for its flagship product, Jeuveau, a neurotoxin used to temporarily improve the appearance of fine lines and wrinkles. Evolus focuses on providing innovative solutions for practitioners and patients seeking non-invasive cosmetic treatments.
Company News
Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather t...
AEON Biopharma announced the grant of 392,158 restricted stock units to newly hired non-executive employees on December 11, 2025, under its 2025 Inducement Incentive Plan. The RSUs vest over four years with 25% vesting annually. The company continues development of ABP-450, a BOTOX biosimilar targeting the $3 billion U.S. therapeutic neurotoxin m...
The article discusses the debut of Chinese boba tea chain Mixue on the Hong Kong stock exchange, the departure of Kroger's CEO due to personal conduct issues, and Domino's introduction of stuffed crust pizza. It also covers the booming med spa industry and the performance of Evolus, a competitor to Botox.
In our monthly Rare Stock Picks series, we're highlighting May 2024 investment picks. Click here for the list of May 2024 Buy recommendations.
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
